MetLife Investment Management LLC Purchases 1,901 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

MetLife Investment Management LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 101,234 shares of the medical research company's stock after acquiring an additional 1,901 shares during the quarter. MetLife Investment Management LLC's holdings in Thermo Fisher Scientific were worth $52,665,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $28,000. Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last ninety days. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Down 1.9 %

Shares of Thermo Fisher Scientific stock traded down $8.38 during trading on Thursday, reaching $423.26. The stock had a trading volume of 2,653,536 shares, compared to its average volume of 1,733,858. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The company has a market capitalization of $159.78 billion, a price-to-earnings ratio of 25.55, a P/E/G ratio of 2.99 and a beta of 0.86. The stock has a fifty day moving average price of $491.37 and a two-hundred day moving average price of $530.03.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.41%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Analysts Set New Price Targets

Several research firms have recently weighed in on TMO. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday. UBS Group cut their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a report on Thursday. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday. Raymond James reissued an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $618.68.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.